Sign inJoin waitlistJoin the waitlist

BG

Benjamin Garmezy

Physician · Verdi Oncology Tennessee PC

Credentials: · · · · · · ·

History

Verdi Oncology Tennessee PC
2024–Present

University of Texas M D Anderson Cancer Center
2018–2021
Michigan State University
2015–2018
Baylor College of Medicine
2011–2015

Research

Clinical and Molecular Characterization of POLE Mutations as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Cancers
JCO Precision Oncology · 2022 · First of 17 authors · 109 citations
Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study
The Lancet · 2024 · 75 citations
Differentiating skin-limited and multisystem Langerhans cell histiocytosis
The Journal of Pediatrics · 2014 · 56 citations

Bradley McGregor
3 papers
Arnab Basu
2 papers
Brian Rini
2 papers
Eric Jonasch
2 papers
Matthew Campbell
2 papers
Matthew Galsky
2 papers
Nizar Tannir
2 papers
Pavlos Msaouel
2 papers · 1 as a resident
Tian Zhang
2 papers
UV
Ulka Vaishampayan
2 papers
Alexander Chehrazi-Raffle
1 paper
Alexandra Drakaki
1 paper

Clinical trials

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Site PI · Recruiting · Phase 3
Eli Lilly and Company
2025–2033
R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors
Site PI · Recruiting · Phase 1
Rise Therapeutics LLC
2025–2029
A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer
Site PI · Recruiting · Phase 1, Phase 2
GlaxoSmithKline
2025–2028
A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)
Site PI · Recruiting · Phase 1
GlaxoSmithKline
2024–2029